{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:53:00Z","timestamp":1787737980404,"version":"build-2784847793"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although the immunotherapy advent has revolutionized cancer treatment, it, unfortunately, does not spare cancer patients from possible immune-related adverse events (irAEs), which can also involve the peripheral nervous system. Immune checkpoint inhibitors (ICIs), blocking cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death ligand 1 (PD-L1), can induce an immune imbalance and cause different peripheral neuropathies (PNs). Considering the wide range of PNs and their high impact on the safety and quality of life for cancer patients and the availability of large post-marketing surveillance databases, we chose to analyze the characteristics of ICI-related PNs reported as suspected drug reactions from 2010 to 2020 in the European real-world context. We analyzed data collected in the European pharmacovigilance database, Eudravigilance, and conducted a systematic and disproportionality analysis. In our study, we found 735 reports describing 766 PNs occurred in patients treated with ICIs. These PNs included Guillain-Barre\u0301 syndrome, Miller-Fisher syndrome, neuritis, and chronic inflammatory demyelinating  polyradiculoneuropathy. These ADRs were often serious, resulting in patient disability or hospitalization. Moreover, our disproportionality analysis revealed an increased reporting frequency of PNs with  tezolizumab compared to other ICIs. Guillain-Barre\u0301 syndrome is a notable potential PN related to ICIs, as it is associated with a significant impact on patient safety and has had unfavorable outcomes, including a fatal one. Continued monitoring of the safety profile of ICIs in real-life settings is necessary, especially considering the increased frequency of PNs associated with atezolizumab compared with other ICIs.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1134436","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T05:30:10Z","timestamp":1678944610000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years"],"prefix":"10.3389","volume":"14","author":[{"given":"Rosanna","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Balzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fraenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Pentella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consiglia","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Donniacuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tesorone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/jamaoncol.2018.6771","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"5","author":"Brown","year":"2019","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/MUS.27014","article-title":"Diabetic neuropathies","volume":"63","author":"Patel","year":"2021","journal-title":"Muscle Nerve"},{"key":"B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/B978-0-444-53480-4.00006-0","article-title":"Diabetic autonomic neuropathy","volume":"126","author":"Freeman","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4045\/TIDSSKR.14.1002","article-title":"Hereditary peripheral neuropathies diagnosed by next-generation sequencing","volume":"135","author":"H\u00f8yer","year":"2015","journal-title":"Tidsskrift den Norske Laegeforening"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3238\/ARZTEBL.2018.0091","article-title":"Hereditary neuropathies","volume":"115","author":"Eggermann","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1212\/CON.0000000000000825","article-title":"Autonomic peripheral neuropathy","volume":"26","author":"Freeman","year":"2020","journal-title":"CONTINUUM Lifelong Learn Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/MUS.26783","article-title":"Nutritional neuropathies","volume":"62","author":"Gwathmey","year":"2020","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/MUS.27069","article-title":"Neuropathies and vitamin d deficiency","volume":"62","author":"Luo","year":"2020","journal-title":"Muscle Nerve"},{"key":"B9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3233\/JND-210630","article-title":"Oxaliplatin neuropathy: Predictive values of skin biopsy, QST and nerve conduction","volume":"8","author":"Kr\u00f8ig\u00e5rd","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040868","article-title":"Neuropathies associated with malignancy","volume":"18","author":"Amato","year":"1998","journal-title":"Semin Neurol"},{"key":"B11","article-title":"Peripheral neuropathy in cancer patients: clinical types, etiology, and presentation. part 2","volume":"4","author":"Forman","year":"1990","journal-title":"Oncol (Williston Park N.Y.)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/J.NCL.2020.03.008","article-title":"Immune-mediated neuropathies","volume":"38","author":"Gwathmey","year":"2020","journal-title":"Neurol Clin"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/S-0030-1267280","article-title":"Treatment of acute immune-mediated neuropathies: Guillain-Barr\u00e9 syndrome and clinical variants","volume":"30","author":"Sederholm","year":"2010","journal-title":"Semin Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/J.AUTREV.2014.01.033","article-title":"Guillain Barr\u00e9 Syndrome and other immune mediated neuropathies: Diagnosis and classification","volume":"13","author":"Hersalis Eldar","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/S40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: An analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/JNS.12339","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J Peripheral Nervous System"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: Illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: Review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANEUROL.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: A systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"774\u201381","DOI":"10.1111\/ENE.15624","article-title":"Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review","volume":"30","author":"Dinoto","year":"2022","journal-title":"Eur J Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.824511\/FULL","article-title":"Neurological manifestations related to immune checkpoint inhibitors: Reverse translational research by using the European real-world safety data","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.965171\/FULL","article-title":"Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study","volume":"13","author":"Mascolo","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.07.014","article-title":"Immune mediated neuropathy following checkpoint immunotherapy","volume":"45","author":"Gu","year":"2017","journal-title":"J Clin Neurosci"},{"key":"B26","unstructured":"Rocha CabreroF\n            MorrisonEH\n          StatPearlsMiller-Fisher syndrome2022"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9800488","article-title":"Guillain-Barr\u00e9 Syndrome-like polyneuropathy associated with immune checkpoint inhibitors: A systematic review of 33 cases","volume":"2021","author":"Li","year":"2021","journal-title":"BioMed Res Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/S00415-020-10213-X","article-title":"Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature","volume":"268","author":"Okada","year":"2021","journal-title":"J Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000070","article-title":"Peripheral neuropathy associated with ipilimumab: A report of 2 cases","volume":"38","author":"Thaipisuttikul","year":"2015","journal-title":"J Immunother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/S00415-021-10404-0\/TABLES\/2","article-title":"Guillain\u2013Barr\u00e9 Syndrome in patients treated with immune checkpoint inhibitors","volume":"268","author":"Fan","year":"2021","journal-title":"J Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.00830","article-title":"Immune checkpoint inhibitors and immune-related adverse drug reactions: Data from Italian pharmacovigilance database","volume":"11","author":"Ruggiero","year":"2020","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21165774","article-title":"Immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors","volume":"21","author":"Vilari\u00f1o","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-32-9636-7_21\/COVER","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"1190","author":"Kuwabara","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s13311-015-0401-7","article-title":"Immunotherapy in peripheral neuropathies","volume":"13","author":"L\u00e9ger","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.774170\/BIBTEX","article-title":"Neurologic toxicity of immune checkpoint inhibitors: A review of literature","volume":"13","author":"Albarr\u00e1n","year":"2022","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00866","article-title":"The association between the incidence risk of peripheral neuropathy and PD-1\/PD-L1 inhibitors in the treatment for solid tumor patients: A systematic review and meta-analysis","volume":"9","author":"Si","year":"2019","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.595655","article-title":"Immune-related neurological toxicities of PD-1\/PD-L1 inhibitors in cancer patients: A systematic review and meta-analysis","volume":"11","author":"Tian","year":"2020","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1336088","article-title":"Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: A systematic review","volume":"17","author":"Eltobgy","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2169\/INTERNALMEDICINE.5629-20","article-title":"Paraneoplastic sensory polyneuropathy related to anti-PD-L1-including anticancer treatment in a patient with lung cancer","volume":"60","author":"Morimoto","year":"2021","journal-title":"Intern Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5692\/CLINICALNEUROL.CN-001562","article-title":"[Atezolizumab-induced Guillain-Barr\u00e9 syndrome-like acute demyelinating polyneuropathy responsive to steroid therapy: a case report]","volume":"61","author":"Yamanaka","year":"2021","journal-title":"Rinsho Shinkeigaku"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/PH15091148","article-title":"Quality of active versus spontaneous reporting of adverse drug reactions in pediatric patients: Relevance for pharmacovigilance and knowledge in pediatric medical care","volume":"15","author":"Dittrich","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"591\u20138","DOI":"10.1016\/J.THERAP.2020.02.022","article-title":"Uses of pharmacovigilance databases: An overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/PDS.3375","article-title":"The EU-ADR web platform: delivering advanced pharmacovigilance tools","volume":"22","author":"Oliveira","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1586\/17512433.2015.992878","article-title":"Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project","volume":"8","author":"Patadia","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINTHERA.2018.09.015","article-title":"On the policy of the Italian government in the discovery, development, and access to medicines","volume":"40","author":"Scavone","year":"2018","journal-title":"Clin Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/PDS.5413","article-title":"Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018","volume":"31","author":"Sultana","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1134436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T05:30:15Z","timestamp":1678944615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1134436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2023.1134436"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1134436","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"1134436"}}